Can early MS patients pause treatment? new trial seeks answers

NCT ID NCT05285891

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo while others continue the drug. Researchers will track relapses and brain scans for another two years to see if stopping is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab (Ocrevus)
What this could lead to: If successful, this could show that some early MS patients may be able to stop treatment without relapse, reducing long-term drug exposure and side effects.
What could go wrong: This is a Phase 4 trial with only 123 participants, so results may not apply to all MS patients. There is a risk of relapse or new brain lesions if treatment is stopped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis Recurrence relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10007, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
MedStar Georgetown University Hospital
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
Oklahoma Medical Research Foundation
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
RWJ Barnabas Health
RECRUITING

Livingston, New Jersey, 07039, United States
The University of Texas Health Science Center at Houston, McGovern Medical School
RECRUITING

Houston, Texas, 77030, United States
University of Massachusetts Memorial Medical Center
RECRUITING

Worcester, Massachusetts, 01655, United States
University of Pennsylvania, Perelman School of Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Rochester Medical Center
RECRUITING

Rochester, New York, 14627, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Virginia Commonwealth University School of Medicine
RECRUITING

Richmond, Virginia, 23298, United States
Yale School of Medicine
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.